Results 91 to 100 of about 11,732 (171)

Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer.

, 2012
199 Background: The ACCORD 11/0402 trial demonstrates that FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) is significantly more efficacious than the current standard of gemcitabine (G) monotherapy in the first line treatment of ...
Stephen Brown, Malcolm J Moore, Cheryl L. Attard, Karine Alloul   +3 more
core   +1 more source

Perioperative Clinical Usage of Phellinus Linteus as a Nutraceutical for Non-FOLFIRINOX-Based Postoperative Adjuvant Chemotherapy for Resected Pancreatic Cancer: A Retrospective Cohort Study

Integrative Cancer Therapies
Introduction: Most patients with pancreatic cancer experience systemic recurrence within 1 to 2 years after radical pancreatectomy. Phellinus linteus (PL) has demonstrated anti-inflammatory, antioxidant, and anti-cancer properties, suggesting potential ...
Juwan Kim MD, Seung Soo Hong MD, Sung Hyun Kim MD, MS, Ho Kyoung Hwang MD, PhD, Chang Moo Kang MD, PhD   +4 more
doaj   +1 more source

Single-institution experience with FOLFIRINOX in advanced pancreatic cancer (PC).

, 2012
330 Background: FOLFIRINOX provides clinically significant benefit in advanced PC compared to gemcitabine (Conroy et al. New Engl J Med 2011;364:1817). Despite superior efficacy, toxicities have tempered enthusiasm for FOLFIRINOX and limited its use in
Stacey Stein, Krishna Soujanya Gunturu, Howard S. Hochster, Jill Lacy, Jaykumar Ranchodbhai Thumar, Kristin Kaley, Xiaopan Yao, Xiangyu Cong, Carol Hahn   +8 more
core   +1 more source

Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study

Cancer Communications, 2018
Background Combination therapy with oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) chemotherapy drastically improves survival of advanced pancreatic cancer patients. However, the efficacy of FOLFIRINOX as a second-line treatment after
Jung Hoon Kim, Sang-Cheol Lee, Sung Yong Oh, Seo-Young Song, Namsu Lee, Eun Mi Nam, Soonil Lee, In Gyu Hwang, Hyo Rak Lee, Kyu Taek Lee, Sang-Byung Bae, Han Jo Kim, Joung Soon Jang, Do Hyoung Lim, Hyun Woo Lee, Seok Yun Kang, Jung Hun Kang   +16 more
doaj   +1 more source

Efficacy of FOLFIRINOX in digestive neuroendocrine carcinoma.

Digestive neuroendocrine carcinomas (NEC) are rare, aggressive, and treatment-resistant malignancies. Platinum and etoposide are recommended as first line treatment; however, with limited benefit in colorectal NEC and in NEC with low Ki67 of 20%-55 ...
Fawad, H, Stokmo, H L, Revheim, M E, Perren, A., Butt, B P, Lothe, I M B, Sorbye, H, Ladekarl, M, Couvelard, A, Tabaksblat, E M, Hjortland, G O, Dybdahl, B   +11 more
core   +1 more source

Non-coding RNA driving chemoresistance in pancreatic cancer: Mechanisms of resistance to FOLFIRINOX and its components 5-fluorouracil and oxaliplatin

Advances in Cancer Biology - Metastasis
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. This is mainly due to intrinsic and acquired resistance to chemotherapy.
Hajar Eftekhari, Amir Sadeghi, Fatemeh Ghadyani, Amirhassan Rabbani, Hesameddin Eghlimi, Binazir Khanabadi, Soudeh Ghafouri-Fard   +6 more
doaj   +1 more source

FOLFIRINOX as first-line chemotherapy in Japanese patients suffering from metastatic pancreatic cancer (KOBE FOLFIRINOX Study)

Background/aim: FOLFIRINOX (oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin) combination chemotherapy is the gold-standard therapy for advanced pancreatic cancer.
籏智, 幸政, Hatachi, Yukimasa, ハタチ, ユキマサ   +2 more
core  

Initial management of locally advanced unresectable or borderline resectable exocrine pancreatic cancer

In this thesis, we discusse the management of nonmetastatic, locally advanced unresectable or borderline resectable exocrine pancreatic cancer (BR-PDAC), specifically pancreatic ductal adenocarcinoma (PDAC).
Amano, Suzuna
core  

Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine FOLFIRINOX in advanced pancreatic cancer: a systematic review

Therapeutic Advances in Medical Oncology, 2019
Background: No clinical trial has directly compared nab-paclitaxel/gemcitabine (nab-P/G) with FOLFIRINOX (fluorouracil/leucovorin/oxaliplatin/irinotecan) in metastatic or advanced pancreatic cancer (mPC or aPC).
Elena Gabriela Chiorean, Winson Y. Cheung, Guido Giordano, George Kim, Salah-Eddin Al-Batran   +4 more
doaj   +1 more source

Living longer with pancreatic cancer: More than FOLFIRINOX?

, 2015
476 Background: Effective treatment for uresectable locally advanced pancreatic cancer (LAPC) or metastatic pancreatic cancer is limited and has a poor prognosis with a five year survival rate of 6.7%.
Nate Koutlas, Punam Punja, Phillip Chae, Prashanti Atluri   +3 more
core   +1 more source